Evaluate the Photoprotection Efficiency of Sunscreen Formulas Under Visible Light Exposure

Exclusion Criteria

• •1. Female who was pregnant or breast feeding or planning a pregnancy during the study,
• •2. Subject having an underlying known disease, or surgical, physical, or medical condition that, in the opinion of the Investigator could interfere with the interpretation of the clinical trial results such as:
• •1. History of recurrent dermatologic conditions (e.g., psoriasis, eczema, urticaria…) or suspicion/history of allergy to cosmetics,
• •2. Any systemic or local disease pathology
• •3. Skin abnormality (scars, excessive hair, tattoos…) at the level of the test zones (middle part of the back),
• •3. Subject who was overexposed to natural (sun) or artificial ultraviolet (tanning lamps) in the last month prior the first visit or who planneda such exposure during the study;
• •4. Subject having history or presenting pathologies induced or aggravated by sun exposure or having abnormal reactions to the sun (ex : photosensitive dermatitis, polymorphic light eruption, solar urticaria, systemic erythematous lupus, dermatomyositis),
• •5. Subject having taken a systemic treatment more than 5 days in the month preceding the inclusion (steroids, nonsteroidal anti-inflammatory drugs such as aspirin, antihistamine, insulin, hypertensors, antibiotics such as quinolones, tetracyclins, thiazids, fluoroquinolons and photosensitising treatment) or any treatment able to induce abnormal response to UV or visible light (vitamin A derivatives, psoralen, aminolevulinic acid etc.) or having plane to take these treatments during the study,
• •6. Subjects having applied a local treatment on the back for more than 2 days during the 2 weeks preceding inclusion (steroids, non-steroidal anti-inflammatories, antihistamines, antibiotics) and all other cosmetic products in the previous 24 hours,
• •7. Subject having antecedents of clinically significant allergy, particularly to study product components,
• •8. Subjects requiring enhanced protection (deprived of liberty, minors, under guardianship),
• •9. Subject being in a situation which, according to the Investigator, could interfere with an optimal participation in the study,
• •10. Subject currently participating or having participated in another clinical trial during the month preceding inclusion,
• •11. Subject under care of guardian or legal guardianship or subject hospitalized in a medical or social establishment for any reason,
• •12. Subject unable to communicate efficiently with the Investigator or being unable to follow the study requirements.